Navigation
Navigation
User login
Back to top
Blue hexagon banner background

Economic models

Follicular lymphoma (FL)

Follicular lymphoma (FL) is the commonest subtype of indolent lymphoma with approximately 1,860 new-cases diagnosed in the UK each year. We have developed an economic model that not only can predict cost and life expectancy of FL patients but also allows users to evaluate the impacts of introducing new treatments or new pathway (please see the tutorial video for details). This innovative approach provides valuable 'real world' evidence to both healthcare providers and commissioners and can support decision-making. Future applications of the model would be particularly useful in the era of personalised medicine.

Economic model

Discrete event simulation

Tutorial video

Follicular lymphoma economic model

Diffuse large B-cell lymphoma (DLBCL)

Diffuse large B-cell lymphoma (DLBCL) is the commonest non-Hodgkin lymphoma. Although rapidly fatal if left untreated, DLBCL is potentially curable.

We have developed an economic model that can predict cost and life expectancy of treating DLBCL patients. The simulation model also allows cost comparison if there is any new drugs added. This is the first economic model using empirical data to provide ‘real world’ evidence of the complete DLBCL treatment pathway. Future application of the model could include evaluation of new technologies/treatments to support healthcare decision makers, especially in the era of personalised medicine.

Economic model

Discrete event simulation

DLBCL economic model structure

Acute myeloid leukaemia (AML)

Acute myeloid leukaemia (AML) is an aggressive cancer, with treatments ranging from supportive care (mainly blood product transfusion) to intensive chemotherapy and stem cell transplantation. These treatments can be expensive, particularly when the costs of managing toxicities and relapse are included.

We have developed an economic model that can predict cost and life expectancy of treating AML patients. The economic model uses population-based data from the Haematological Malignancy Research Network. The robust model can be used to evaluate new diagnostic tools/treatments, as well as enable policy makers to make informed decisions.

Economic model

Download Excel workbook

AML economic model structure

Publications